英国周二起展开大规模接种新冠疫苗计划 美国最快本周内安排紧急接种
英国政府最快周二开始为民众接种由辉瑞及BioNTech研发的新冠病毒疫苗,首批4,000万剂疫苗已运抵英国。
英国是首个展开大规模接种的国家,首批疫苗会优先为80岁以上长者、前线医护人员及院舍员工接种。据悉,英女王伊利沙伯二世及菲腊亲王不会获得优待,会按照机制轮候。
另外,美国本周四将决定是否授权紧急使用辉瑞(PFE.US)及BioNTech(BNTX.US)研发的疫苗,一旦获批,最快可於本周内开始分阶段让民众紧急接种。
白宫专家小组表示,分发疫苗工作已准备妥当,预计疫苗效力可以维持多年,而长者及其他高风险人士则需要每隔3至5年进行补充注射。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.